1	Sex-specific Risk Factors for Survival in B-cell Non-Hodgkin Lymphoma Patients after Anti-CD19
2	CAR T-Cell Therapy
3	
4	Manishkumar S. Patel <sup>1</sup> , Agrima Mian <sup>2</sup> , Akansha Jalota <sup>1</sup> , Peter Bazeley <sup>3</sup> , Sujata Patil <sup>3,4</sup> , Brian T. Hill <sup>2</sup> , and
5	Neetu Gupta <sup>1</sup>
6	
7	<sup>1</sup> Department of Inflammation and Immunity, Lerner Research Institute; <sup>2</sup> Department of Hematology and
8	Medical Oncology, Taussig Cancer Institute; <sup>3</sup> Department of Quantitative Health Sciences, Lerner
9	Research Institute; <sup>4</sup> Department of Cancer Biostatistics, Taussig Cancer Institute, Cleveland Clinic,
10	Cleveland, OH
11	
12	Correspondence to: Neetu Gupta, Ph.D.; 9500 Euclid Avenue, NE40, Cleveland, OH 44195; Email:
13	guptan@ccf.org; Phone: (216) 444-7455; Fax: (216) 444-9329
14	
15	Running Title: Sex-specific risk factors in CAR T-cell therapy
16	Keywords: CAR T-cells, lymphoma, survival, biological sex
17	

# 19 Abstract

20 Sex bias is well documented in autoimmune diseases, cancer and immune responses to infectious agents. 21 Here, we investigated if pre-treatment risk factors that influence the survival of B-cell non-Hodgkin lymphoma (NHL) patients after anti-CD19 CAR T-cell therapy are sexually dimorphic. We measured 22 23 pre-leukapheresis tumor burden (lactate dehydrogenase levels), C-reactive protein (CRP) and serum 24 cytokine and chemokine concentration in 67 B-cell NHL patients treated with axicabtagene ciloleucel 25 (axi-cel) or tisagenlecleucel (tisa-cel). Association of relative abundance of each factor with progression-26 free survival (PFS) and overall survival (OS) was analyzed in male and female patients together, or only 27 within the male cohort or only within the female cohort. No differences in PFS or OS or in pre-treatment 28 tumor burden, CRP and cytokine/chemokine levels were observed between male and female patients 29 undergoing axi-cel or tisa-cel therapy. However, within the male group, patients with higher pre-treatment 30 tumor burden and greater relative abundance of CRP and pro-inflammatory cytokines and chemokines 31 conferred greater risk of poor progression-free survival (PFS) and/or overall survival (OS). In contrast, within the female group, patient survival was largely agnostic to variations in tumor burden, CRP and 32 33 cytokine/chemokine abundance. Specifically, higher relative abundance of IL-6, IL-8, IL-27, TNF- $\alpha$ , 34 Eotaxin-1, MIP-1 $\beta$  and MCP-1 was associated with poor PFS and/or OS after CAR T-cell therapy within 35 the male group, whereas higher IL-27 and IFN $\alpha$ 2 abundance was associated with better PFS and poorer 36 OS, respectively, within the female group. Our data suggest that biological sex may modulate the impact 37 of baseline risk factors on survival outcomes of CAR T-cell therapy in B-cell NHL.

# 39 Introduction

Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy demonstrates remarkable efficacy for the 40 41 treatment of refractory/relapsed (r/r) large B-cell lymphoma (LBCL), follicular lymphoma and mantle cell lvmphoma<sup>1-3</sup>. However, ~40-60% of patients treated with CAR-T cell therapy exhibit poor response and 42 survival<sup>14</sup>. This has spurred the need to identify pre-treatment biomarkers of response to anti-CD19 CAR 43 44 T-cell therapy. In addition to tumor characteristics and intrinsic composition/attributes of CAR-T cells, 45 the inter-patient heterogeneity in immunological signatures may influence response to this therapy. 46 Further, factors that do not directly stem from the immune system, such as sex, race and ethnicity may 47 play a role in modulating and/or predicting the survival of patients undergoing CAR T-cell therapy. Indeed, race and ethnicity were recently shown to contribute to the differences in response to CAR T-cell 48 therapy<sup>5</sup>. However, as race and ethnicity are more complex to define, self-reported race is widely 49 recognized as an incomplete interpretation of genetic ancestry or human genetic variation<sup>6</sup>. Further, as 50 reporting these variables is not mandatory<sup>7</sup> and complete medical records for race and ethnicity are not 51 52 available for all patients seen at Cleveland Clinic, the present study is unable to address the impact of race 53 and ethnicity on outcomes.

54

55 On the other hand, it is well-established that the male and female immune systems are different, and that immune responses to infections<sup>8</sup>, many autoimmune diseases<sup>9-11</sup>, and tumor pathology<sup>12,13</sup> exhibit sex 56 bias. Sex differences can alter the tumor microenvironment<sup>14</sup> and modulate immune system homeostasis 57 and responses via inflammatory cytokine production<sup>15</sup>, <sup>16</sup>. The impact of sex has also been reported in the 58 efficacy<sup>17</sup> and survival outcomes of patients<sup>18</sup> receiving immune checkpoint inhibitors for solid tumors. 59 60 Therefore, baseline tumor burden and cytokine/chemokine profiles in male and female patients may 61 differentially impact the survival outcomes of anti-CD19 CAR T-cell therapy. Understanding these 62 differences may provide insights into sex-specific biomarkers of survival and enable better stratification

of outcomes. As biological sex at birth is reported for all patients undergoing anti-CD19 CAR T-cell
 therapy, we focused on investigating potential differences in outcomes based on baseline features of
 responding and non-responding male and female cohorts.

66

67 We examined if baseline cytokine/chemokine levels and tumor burden affect the survival of LBCL 68 patients treated with axicabtagene ciloleucel (axi-cel) or tisagenlecleucel (tisa-cel) in a sex-specific 69 manner. We demonstrate that male B-NHL patients with elevated baseline abundance of IL-8, IL-6, IL-70 27, Eotaxin-1, MIP-1 $\beta$ , MCP-1, TNF- $\alpha$  and CRP, as well as higher pre-treatment tumor burden exhibit 71 poorer survival compared to those with lower abundance of these factors. On the other hand, within the 72 female patient cohort, the survival outcomes are largely unaffected by the relative abundance of these 73 factors. Our data suggest that an unfavorable baseline circulating cytokine/chemokine profile and high 74 pre-treatment tumor burden may collaborate to lower the survival of male patients undergoing anti-CD19 75 CAR T-cell therapy.

# 77 Materials and Methods

# 78 Patient enrollment, specimen collection protocol, and clinical data

79 All patients with r/r B-cell NHL (n=67) who received treatment with axi-cel (n=45) or tisa-cel (n=22) 80 between 2018 and 2021 and gave informed consent for blood sample collection were included in this 81 IRB-approved study, which was executed in accordance with the declaration of Helsinki. In addition to 82 routine blood collection for clinical care, peripheral blood was also collected on the day of leukapheresis 83 (baseline) and serum was stored for inclusion in the institutional biorepository. The patient cohort is 84 represented by 46 males and 21 females and represents the observed male/female ratio within the B-NHL 85 population<sup>19,20</sup>. Baseline clinical characteristics and demographic details were retrieved through an IRB-86 approved retrospective chart review of the electronic medical record system and maintained in a secure 87 and HIPPA-compliant Research Electronic Data Capture (REDCap) system. Clinical outcomes including 88 progression-free survival (PFS) and overall survival (OS) were recorded relative to the date of CAR T-89 cell infusion. Patients who did not experience the event by the end of the study period or lost to follow-up were censored for these time-to-event outcomes. Circulating lactate dehydrogenase (LDH) and C-reactive 90 91 protein (CRP) levels were measured on the day of leukapheresis.

92

# 93 Cytokine/Chemokine and tumor burden quantification

Multiplexed bead arrays (Eve Technologies, Alberta, Canada) were used to quantify serum levels of 29
cytokines and chemokines, including IL-1RA, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-15, IL18, IL-21, IL-27, IFNα2, IFN-γ, TNF-α, Eotaxin-1, MIP-1α, MIP-1β, MCP-1, Flt3L, Fractalkine, G-CSF,
GM-CSF, IP-10, MDC, RANTES, sCD40L and VEGF-A.

98

# 99 Data processing and quality control

100 Cytokine/chemokine levels were measured in three batches. Cytokines with >20% of missing values (Out 101 of range-OOR) across patients in each batch were removed. Cytokines with  $\leq 20\%$  missing values were imputed as follows<sup>21</sup>. OOR values were replaced with median values; OOR < (out of range at the lower 102 103 end) and OOR> (out of range at the higher end) were imputed with half of the minimum observed value 104 across all samples and double of the maximum value observed across all samples, respectively. The 105 concentrations were log-transformed and a PCA plot was generated (Supplemental Fig. 1A) to identify 106 batch effects, using the PCA function in the FactoMineR package. Batch correction was performed using 107 "scale and center" in R and the removal of batch effects was again confirmed by generating a PCA plot 108 (Supplemental Fig. 1B). Batch-corrected relative abundance of each cytokine/chemokine was used for the 109 analysis of association with survival outcomes.

110

# 111 Assessment of clinical response

112 Response assessment was performed 3 months after CAR T-cell therapy using the Lugano classification 113 system and defined as a complete metabolic response, partial response, stable disease, or progressive 114 disease, based on FDG uptake on PET- $CT^{22}$ . Response groups were defined based on ORR = overall 115 response rate (includes complete response [CR] and partial response (PR)), and NR = no response 116 (includes progressive disease [PD], stable disease [SD], death).

117

# 118 Association and statistical analysis

119 These analyses had two main goals: to evaluate differences in tumor burden (i.e. LDH), CRP,

120 and each cytokine/chemokine by sex and to evaluate the association of tumor burden, CRP, and

121 each cytokine/chemokine with OS and PFS by sex. Due to skewness, all cytokine, chemokine,

122 LDH and CRP values were log-transformed prior to analysis. These variables were also made

binary at established cutoffs or if no established cutoffs existed, at the sex-specific median.

- 124 Specifically, for LDH, the indication for tumor burden was calculated using two established
- 125 cutoffs: one at  $\geq 250 \text{ U/l}^{23}$  and the other at  $\geq 400 \text{ U/l}^{24}$ . For all other cytokines and chemokines,
- 126 cutoffs at sex-specific medians were used. Differences in each continuous variable by sex was
- 127 assessed using a two-sample Wilcoxon test. For males and females separately, the association of
- each binary variable with OS and PFS was assessed using the Kaplan-Meier method and the log-
- 129 rank test. We note that the number of males vs females in the present cohort differs, and thus
- 130 comparing significance by sex is not valid. We also note that our analyses and results are
- 131 hypothesis generating and as such, the findings will require validation in a larger, separate
- dataset. No adjustments for multiple comparisons are made. All statistical analyses were
- performed using R v4.1.0 and p-values <0.05 were considered significant.

# 135 Results

136 Baseline and post-treatment clinical characteristics of the r/r B-NHL patient cohort treated with anti-137 CD19 CAR T-cells are shown in Table 1. The median age was 63 years (range 25-77), and 68.7% of 138 patients in the cohort were male. The median age of males and females was 64.5 years (range 25-77) and 139 61 years (range 30-74), respectively. The clinical diagnosis was diffuse large B-cell lymphoma (DLBCL) 140 (n = 46, males=35, females=11), transformed follicular lymphoma (n = 12, males=5, females=7), or primary mediastinal B-cell lymphoma (n = 7, males=5, females=2), and 40.3% of the patients had 141 142 received prior autologous stem cell transplantation. Axi-cel was received by 45 patients (males=29, 143 females=16) and tisa-cel was received by 22 patients (males=17, females=5). The median durations for 144 overall survival (OS) and progression-free survival (PFS) were 332 days and 134 days, respectively.

145

# 146 High baseline tumor burden and CRP are associated with poor survival in male patients

147 We first investigated if there is sex bias in overall and progression-free survival of B-cell NHL patients 148 treated with anti-CD19 CAR T cells. Similar to previous findings in pediatric B-ALL patients treated with CD19-directed CAR T-cells<sup>25</sup>, male and female r/r B-cell NHL patients did not show a significant 149 150 difference in the probability of OS (Supplemental Fig. 2A) or PFS (Supplemental Fig. 2B) upon CAR T-151 cell therapy. Additionally, the abundance of established baseline risk factors such as tumor burden 152 (measured as LDH) (Supplemental Fig. 2C) and CRP (Supplemental Fig. 2D) were not different between 153 male and female patients in our cohort. Next, we examined if tumor burden and CRP have different 154 associations with survival when the male and female groups and analyzed separately. A previous study 155 used  $\geq$ 250 U/l LDH to stratify high and low tumor burden and identified this marker as the sole predictor of survival<sup>23</sup>; therefore, initially we first used the same cut-off in our analysis. Patients who had  $\geq 250 \text{ U/l}$ 156 157 LDH prior to treatment were at greater risk of poor PFS and OS after axi-cel (n=45) and tisa-cel (n=22) 158 therapy compared to those with <250 U/l LDH (Fig. 1A). Importantly, while male patients with  $\geq 250$  U/l 159 LDH had poorer PFS and OS compared to those with <250 U/l LDH (Fig. 1B), there was no association 160 between LDH concentration and OS or PFS in female patients (Fig. 1C). Next, because >400 U/I LDH

was reported to be associated with poor PFS in patients receiving anti-CD19 CAR T-cell therapy<sup>24</sup>, we 161 also performed association analysis using this cut-off. We found that  $\geq 400$  U/l LDH was significantly 162 163 associated with poor PFS and OS in all patients, and in the male only group, but not in the female only 164 group (Supplemental Fig. 3). Among pre-treatment circulating biomarkers, CRP is an important regulator 165 of inflammation and elevated serum CRP is known to be associated with poor PFS or OS after CAR Tcell therapy in multiple myeloma patients<sup>26</sup>, and DLBCL patients after CAR T-cell therapy<sup>27</sup> or 166 chemotherapy<sup>28</sup>. Hence, we further investigated if CRP levels were associated with differential survival 167 168 outcomes in separate male and female cohorts. Elevated CRP was significantly associated with poor OS 169 when considering both male and female patients together (Fig. 2A, P=0.0172) or males alone (Fig. 2B, 170 P=0.007), but no association was observed in the female only cohort (Fig. 2C, P=0.7336). On the other hand, elevated CRP was not significantly associated with poor PFS in male and female patients together 171 172 (Fig. 2A, P=0.0932) or only males (Fig. 2B, P=0.1028) or only females (Fig. 2C, P=0.5199). It is 173 important to note that while above median CRP abundance showed a trend of association with poor PFS 174 in male and female patients together (Fig. 2A) and only in males (Fig. 2B), this trend was not evident in 175 the female only cohort (Fig. 2C).

176

# High abundance of IL-6, IL-8, IL-27, Eotaxin-1, MIP-1β and MCP-1 associated with poor survival in male patients

Because CRP is an important inflammatory biomarker, we examined if the pre-treatment levels of other
serum cytokines/chemokines that mediate inflammation during CAR T-cell therapy were different
between male and female patients. For this study, we chose 29 cytokines/chemokines (IL-1RA, IL-3, IL4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-15, IL-18, IL-21, IL-27, IFNα2, IFN-γ, TNF-α, Eotaxin-1, MIP1α, MIP-1β, MCP-1, Flt3L, Fractalkine, G-CSF, GM-CSF, IP-10, MDC, RANTES, sCD40L and VEGFA) that are of myeloid and lymphoid origin and play essential roles in innate and/or adaptive immunity.
With the exception of IL-3, the relative abundance of baseline circulating cytokines and chemokines was

186 not significantly different between male and female patients (Fig. 3). We reasoned that despite no 187 observable differences in abundance, these cytokine/chemokines may have different interactions with the 188 male vs. female immune environment and could therefore be associated differentially with survival in 189 each sex. To investigate this, the association of cytokine abundance with survival was analyzed separately 190 for only male, only female or both sexes together. The relative abundance of specific 191 cytokines/chemokines within each cohort was classified as either below or above median, and median 192 abundance is indicated for each cohort and cytokine in PFS and OS association analysis. When both sexes 193 were analyzed together, poorer PFS was found to be associated with higher abundance of MIP-1 $\beta$  and 194 Eotaxin-1 (P<0.05), and IL-8 (P=0.074) (Fig. 4). When associations of cytokine abundance with PFS 195 were analyzed separately in male only and female only patients, higher abundance of IL-8, Eotaxin-1, 196 MIP-16 (P<0.05), IL-6 (P=0.075), and MCP-1 (P=0.086) were associated with poor PFS in male patients 197 (Fig. 4). The abundance of these cytokines had no observable associations with PFS in the female only 198 cohort but elevated IL-27 was significantly associated with better PFS in females (Fig. 4). Higher relative 199 abundance of IL-6, IL-8, IL-27, Eotaxin-1, MCP-1, and TNF- $\alpha$  was also significantly associated (P<0.05) 200 with poorer OS when considering the male only cohort; but no observable difference in OS was found in 201 the female only cohort for these cytokines. (Fig. 5). Interestingly,  $IFN\alpha^2$  was the only cytokine whose 202 higher relative abundance was associated with poor OS (P=0.07) within the female only cohort (Fig. 5). 203 Higher abundance of IL-6 was associated (P<0.05) with poor OS when male and female sexes were 204 analyzed together or in the male only cohort, but no association was observed in the female only cohort 205 (Fig. 5). While IL-7 is an important T-cell promoting cytokine, its pre-treatment abundance was not 206 associated with PFS (Fig. 4) or OS (Fig. 5). Additionally, the relative abundance of IL-1RA, IL-3, IL-4, 207 IL-9, IL-10, IL-15, IL-18, IL-21, Flt3L, Fractalkine, G-CSF, GM-CSF, IP-10, MDC, RANTES, sCD40L, and VEGF-A showed no association with PFS (Supplemental Fig. 4) or OS (Supplemental Fig. 5) in male 208 209 or female patients. These data indicate that despite similar overall abundance of the analyzed cytokines in 210 male and female r/r B-NHL patients, the association of their individual relative abundance with survival 211 after anti-CD19 CAR T-cell therapy varies in a sex-biased manner.

212

- 213 Taken together, our results demonstrate that higher tumor burden, CRP, IL-6, IL-27, TNF-α, IL-8,
- Eotaxin-1, MIP-1β and MCP-1 represent a novel signature of poor survival in male, but not female B-
- 215 NHL patients treated with anti-CD19 CAR T-cells.

# 217 Discussion

218 A variety of pre-treatment biomarkers of clinical outcomes have been reported in LBCL patients undergoing anti-CD19 CAR T-cell therapy<sup>29,30</sup>. However, the impact of sex on the association between 219 220 pre-treatment tumor and immune environment and survival after CAR T-cell therapy has not been comprehensively explored. Here, we demonstrate that higher baseline tumor burden and greater relative 221 222 abundance of a pre-treatment inflammatory signature consisting of IL-8, IL-6, TNF-a, Eotaxin-1, MIP-223 1β, MCP-1 and CRP confers risk of poor survival in male patients treated with anti-CD19 CAR T-cells. 224 On the other hand, female patients undergoing CAR T-cell therapy do not show an association between 225 the relative abundance of these pre-treatment biomarkers and survival. Our findings are consistent with 226 the tenet that the immune system has different interactions in the male and female sex and that this plays a 227 role in establishing sex differences in response to immunotherapy.

228

229 A pan-cancer analysis demonstrated sex as a significant factor influencing cancer-specific survival and females have better prognosis than male patients in most cancers<sup>31</sup>. In B-cell lymphoma patients, the male 230 sex is an adverse prognostic factor when treated with immunochemotherapy but not when treated with 231 chemotherapy<sup>32</sup>. Our finding that higher baseline tumor burden predisposes only male patients to a poor 232 233 survival outcome indicates sex bias in outcomes of CAR T-cell therapy. Specific components of tumors 234 in males may play a role in this predisposition, such as high circulating cytokine levels and monocytic-235 myeloid-derived suppressor cells (mMDSCs), both of which are associated with resistance to CAR T-cell therapy<sup>30</sup>. Interestingly, males have higher levels of mMDSCs in general<sup>33</sup> and this is thought to be one of 236 237 the sex-specific mechanisms that prevents autoimmune diseases and underlies poorer response to infections<sup>34</sup>. Along these lines, CRP, another known biomarker of poor prognosis in r/r DLBCL after 238 CAR T-cell therapy<sup>27</sup>, was reported to support the expansion of MDSCs and suppression of T cell 239 proliferation<sup>35</sup>. It is conceivable that male patients with larger tumor burden have higher levels of 240

241 mMDSCs which interfere with CAR T-cell activity. Therefore, the association of higher pre-treatment 242 CRP and tumor burden with poor survival suggests the existence of an unfavorable immune environment 243 in male r/r B-NHL patients that may limit optimal CAR T-cell activity.

244

245 Inflammatory cytokines and chemokines are important for the activation of T cell-mediated immune 246 reactions and recruitment of myeloid cells, and together these soluble factors facilitate CAR T-cell activity<sup>36-38</sup>. Remarkably, we did not observe a significant difference in the serum abundance of 247 248 cytokines/chemokines between male and female r/r B-NHL patients treated with anti-CD19 CAR T-cells, 249 with the exception of IL-3. Yet, in male patients, higher pre-treatment abundance of IL-6, IL-8, IL-27, 250 TNF- $\alpha$ , Eotaxin-1 and MIP-1 $\beta$  confers risk of poor survival outcomes. As these associations are not 251 observed in female patients, our findings indicate that the manner in which these cytokines interact with 252 the male environment may be different from that in the female environment, and likely confers poor 253 survival probability in the former. Interestingly, IL-6, TNF- $\alpha$ , IL-8, MIP-1 $\beta$  and MCP-1 are known to be 254 associated with tumor burden and tumor growth in various cancers<sup>39-42</sup>. High tumor burden is associated with the IL-6 signaling pathway<sup>43</sup> and with elevated levels of TNF- $\alpha^{44}$  and CRP<sup>45</sup> in aggressive cancers. 255 256 Additionally, inflammatory stimuli such as IL-6 can indirectly induce the expression of chemokine mediators such as MCP-1<sup>46-48</sup> which recruit MDSCs and support tumor growth<sup>49</sup>. Eotaxin-1 is a CC 257 subfamily chemokine similar to MCP- $1^{47}$  and is reported to inhibit antitumor immunity<sup>50,51</sup>. Therefore, the 258 259 association of higher relative abundance of IL-8, IL-6, TNF- $\alpha$ , Eotaxin-1, MIP-1 $\beta$  and MCP-1with poor 260 survival probability in the male patients suggests a unique interaction network between the tumor and circulating environments that predisposes male patients to poorer survival outcomes after anti-CD19 CAR 261 T-cell therapy. Indeed, some of these interactions may be mediated by sex hormones<sup>52</sup>, social 262 behaviors<sup>53,54</sup>, chromosomal genetics<sup>55</sup>, and sex chromosome-encoded genetic environment in the male 263  $\text{sex}^{56}$ . 264

265

266 While a majority of associations described here impact survival outcomes in male r/r B-NHL patients, 267 there were notable associations between abundance of two cytokines with survival in female r/r B-NHL 268 patients – IL-27 and IFN $\alpha$ 2. Female patients with higher relative abundance of IL-27 showed significant 269 association with better PFS, and those with higher abundance of IFN $\alpha$ 2 showed poorer OS. IL-27 is a 270 pleiotropic cytokine with both pro- and anti-inflammatory activities and IL-27 expressing T cells demonstrate sustained anti-tumor immunity and cytotoxicity<sup>57</sup>. Interestingly, our data reveal context-271 272 specific associations of this cytokine – in male patients elevated abundance increases risk of poor overall 273 survival, yet in female patients, higher abundance of IL-27 predicts better progression-free survival. The 274 molecular basis of this difference is unclear and deserves future investigation. Type I IFNs, specifically 275 IFN $\alpha$ , are a primary source of pathogenesis in autoimmune diseases such as systemic lupus erythematosus that exhibit a strong female sex bias<sup>58</sup>. Therefore, female r/r B-NHL patients who have 276 277 higher abundance of IFN $\alpha$ 2 may experience similar inflammatory pathologies that affect their overall 278 survival after CAR T-cell therapy. The mechanistic basis of the unique associations between the 279 abundance of IL-27 and IFN $\alpha$ 2 and survival in only the female patients in our cohort is currently unclear and will need to be further investigated. 280

281

A few limitations should be considered when inferring the findings of our study. First, the relatively small sample size currently limits the generalizability our findings to a larger population. Further, other factors, such as ethnicity, race, type of lymphoma, type of CAR T-cell therapy and the use of bridging therapy may influence the outcome of CAR T-cell therapy response in a sexually dimorphic manner. We were unable to investigate these factors, either due to lack of available data or small cohort size. Despite these limitations, our pilot study suggests that the observed differences in clinical survival outcome in male and female patients are primarily driven by different biological interactions of cytokines and tumor

289 microenvironment in each sex. Further research is needed to validate this hypothesis and explore the 290 underlying mechanisms.

291

292	In summary, our study reveals sex bias in the association of pre-treatment clinical and molecular
293	biomarkers with clinical outcomes of CAR T-cell therapy in r/r B-NHL patients, and underscores the
294	importance of acknowledging sexual dimorphism in the risk factors associated with outcomes of
295	personalized cell-based immunotherapies. Stratifying the outcomes separately in male and female patients
296	may provide avenues for gender specific adaptations of CAR-T cell treatment.

# 298 Acknowledgments

299	This study was funded by VeloSano Bike to Cure, Cleveland Clinic Center of Excellence in Lymphoid
300	Malignancies Research, and Taussig Cancer Institute. The authors thank the patients who consented to
301	this study, as well as clinical nurses and coordinators who contributed meaningful effort to this study.

302

# 303 Authorship Contributions

M.S.P. and A.J. collected and processed the blood samples; M.S.P. and A.M. collected clinical data; M.S.P., P.B., S. P., B.T.H., and N.G. analyzed the data; M.S.P., S.P., B.T.H., and N.G. wrote the manuscript; B.T.H. and N.G. provided funding support; and N.G. conceptualized and supervised the study.

308

# 309 Disclosure of Potential Conflicts of Interest

B.T.H. has received research funding from Takeda; Consultancy, Honoraria, Research Funding from
Genentech, Karyopharm, Celgene, Abbvie, Pharmacyclics, Beigene, AstraZenica, Kite, a Gilead
Company, BMS; Consultancy, Honoraria from Novartis.

313

# 314 Data sharing statement

For original data, please contact the corresponding author (guptan@ccf.org).

# 316 References

317	1.	Nastoupil LJ, Jain MD, Feng L, et al. Standard-of-Care Axicabtagene Ciloleucel for Relapsed or
318	Refra	actory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium. J Clin Oncol.
319	2020	;38(27):3119-3128.

- Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene Ciloleucel CAR T-Cell Therapy in
   Refractory Large B-Cell Lymphoma. *N Engl J Med.* 2017;377(26):2531-2544.
- Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in Adult Relapsed or Refractory
   Diffuse Large B-Cell Lymphoma. *N Engl J Med*. 2019;380(1):45-56.
- 4. Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma:

results from the international SCHOLAR-1 study. *Blood*. 2017;130(16):1800-1808.

- Locke FL, Siddiqi T, Jacobson CA, et al. Real-world and clinical trial outcomes in large B-cell
  lymphoma with axicabtagene ciloleucel across race and ethnicity. *Blood*. 2024;143(26):2722-2734.
- Mersha TB, Abebe T. Self-reported race/ethnicity in the age of genomic research: its potential
  impact on understanding health disparities. *Hum Genomics*. 2015;9(1):1.
- Turner BE, Steinberg JR, Weeks BT, Rodriguez F, Cullen MR. Race/ethnicity reporting and
  representation in US clinical trials: A cohort study. *The Lancet Regional Health Americas*. 2022;11.
- 8. Klein SL. The effects of hormones on sex differences in infection: from genes to behavior.
   *Neurosci Biobehav Rev.* 2000;24(6):627-638.
- Afshan G, Afzal N, Qureshi S. CD4+CD25(hi) regulatory T cells in healthy males and females
  mediate gender difference in the prevalence of autoimmune diseases. *Clin Lab.* 2012;58(5-6):567-571.
- Billi AC, Kahlenberg JM, Gudjonsson JE. Sex bias in autoimmunity. *Curr Opin Rheumatol*.
  2019;31(1):53-61.

Rubtsova K, Marrack P, Rubtsov AV. Sexual dimorphism in autoimmunity. *J Clin Invest*.
2015;125(6):2187-2193.

Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. *Science*.
2018;359(6382):1350-1355.

Wang PF, Song HF, Zhang Q, Yan CX. Pan-cancer immunogenomic analyses reveal sex
disparity in the efficacy of cancer immunotherapy. *Eur J Cancer*. 2020;126:136-138.

Saad M, Tan AC, Naqa IE, et al. 88 Evidence of enhanced immune activation within the tumor
microenvironment and the circulation of female patients with high-risk melanoma compared to males. *J Immunother Cancer*. 2021;9(Suppl 2):A96-A96.

15. Lefèvre N, Corazza F, Valsamis J, et al. The Number of X Chromosomes Influences
Inflammatory Cytokine Production Following Toll-Like Receptor Stimulation. *Front Immunol.*2019;10:1052.

Berghella AM, Contasta I, Lattanzio R, et al. The Role of Gender-specific Cytokine Pathways as
Drug Targets and Gender- specific Biomarkers in Personalized Cancer Therapy. *Curr Drug Targets*.
2017;18(4):485-495.

353 17. Santoni M, Rizzo A, Mollica V, et al. The impact of gender on The efficacy of immune
354 checkpoint inhibitors in cancer patients: The MOUSEION-01 study. *Crit Rev Oncol Hematol.*355 2022;170:103596.

18. Grassadonia A, Sperduti I, Vici P, et al. Effect of Gender on the Outcome of Patients Receiving
Immune Checkpoint Inhibitors for Advanced Cancer: A Systematic Review and Meta-Analysis of Phase
III Randomized Clinical Trials. *J Clin Med.* 2018;7(12):542.

Burkhardt B, Zimmermann M, Oschlies I, et al. The impact of age and gender on biology, clinical
features and treatment outcome of non-Hodgkin lymphoma in childhood and adolescence. *Br J Haematol*.
2005;131(1):39-49.

Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS. Lymphoma incidence
patterns by WHO subtype in the United States, 1992-2001. *Blood*. 2006;107(1):265-276.

Jalota A, Hershberger CE, Patel MS, et al. Host metabolome predicts the severity and onset of
acute toxicities induced by CAR T-cell therapy. *Blood Advances*. 2023;7(17):4690-4700.

22. Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and
response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. *J Clin Oncol.*2014;32(27):3059-3068.

369 23. Suguro M, Kanda Y, Yamamoto R, et al. High serum lactate dehydrogenase level predicts short
370 survival after vincristine-doxorubicin-dexamethasone (VAD) salvage for refractory multiple myeloma.
371 *Am J Hematol.* 2000;65(2):132-135.

Karschnia P, Jordan JT, Forst DA, et al. Clinical presentation, management, and biomarkers of
neurotoxicity after adoptive immunotherapy with CAR T cells. *Blood*. 2019;133(20):2212-2221.

Faruqi AJ, Ligon JA, Borgman P, et al. The impact of race, ethnicity, and obesity on CAR T-cell
therapy outcomes. *Blood Adv.* 2022;6(23):6040-6050.

Liu Y, Jie X, Nian L, et al. A combination of pre-infusion serum ferritin, CRP and IL-6 predicts
outcome in relapsed/refractory multiple myeloma patients treated with CAR-T cells. *Frontiers in Immunology*. 2023;14.

Vercellino L, Di Blasi R, Kanoun S, et al. Predictive factors of early progression after CAR T-cell
therapy in relapsed/refractory diffuse large B-cell lymphoma. *Blood Adv.* 2020;4(22):5607-5615.

Troppan KT, Schlick K, Deutsch A, et al. C-reactive protein level is a prognostic indicator for
survival and improves the predictive ability of the R-IPI score in diffuse large B-cell lymphoma patients. *British Journal of Cancer.* 2014;111(1):55-60.

Faramand R, Jain M, Staedtke V, et al. Tumor Microenvironment Composition and Severe
Cytokine Release Syndrome (CRS) Influence Toxicity in Patients with Large B-Cell Lymphoma Treated

with Axicabtagene Ciloleucel. *Clin Cancer Res.* 2020;26(18):4823-4831.

387 30. Jain MD, Zhao H, Wang X, et al. Tumor interferon signaling and suppressive myeloid cells are
associated with CAR T-cell failure in large B-cell lymphoma. *Blood*. 2021;137(19):2621-2633.

389 31. He Y, Su Y, Zeng J, et al. Cancer-specific survival after diagnosis in men versus women: A pan390 cancer analysis. *MedComm* (2020). 2022;3(3):e145.

32. Riihijärvi S, Taskinen M, Jerkeman M, Leppä S. Male gender is an adverse prognostic factor in
B-cell lymphoma patients treated with immunochemotherapy. *Eur J Haematol*. 2011;86(2):124-128.

393 33. Bayik D, Zhou Y, Park C, et al. Myeloid-Derived Suppressor Cell Subsets Drive Glioblastoma
394 Growth in a Sex-Specific Manner. *Cancer Discov.* 2020;10(8):1210-1225.

34. Kiaee F, Jamaati H, Shahi H, et al. Immunophenotype and function of circulating myeloid
derived suppressor cells in COVID-19 patients. *Scientific Reports*. 2022;12(1):22570.

397 35. Jimenez RV, Kuznetsova V, Connelly AN, Hel Z, Szalai AJ. C-Reactive Protein Promotes the
398 Expansion of Myeloid Derived Cells With Suppressor Functions. *Front Immunol.* 2019;10:2183.

399 36. Umansky V, Blattner C, Gebhardt C, Utikal J. The Role of Myeloid-Derived Suppressor Cells

400 (MDSC) in Cancer Progression. *Vaccines (Basel)*. 2016;4(4):36.

37. Schlecker E, Stojanovic A, Eisen C, et al. Tumor-infiltrating monocytic myeloid-derived
suppressor cells mediate CCR5-dependent recruitment of regulatory T cells favoring tumor growth. J *Immunol.* 2012;189(12):5602-5611.

38. Salomon BL, Leclerc M, Tosello J, Ronin E, Piaggio E, Cohen JL. Tumor Necrosis Factor α and
Regulatory T Cells in Oncoimmunology. *Front Immunol*. 2018;9:444.

39. Sanmamed MF, Carranza-Rua O, Alfaro C, et al. Serum interleukin-8 reflects tumor burden and
treatment response across malignancies of multiple tissue origins. *Clin Cancer Res.* 2014;20(22):56975707.

409 40. Gazzaniga S, Bravo AI, Guglielmotti A, et al. Targeting Tumor-Associated Macrophages and
410 Inhibition of MCP-1 Reduce Angiogenesis and Tumor Growth in a Human Melanoma Xenograft. *Journal*411 *of Investigative Dermatology*. 2007;127(8):2031-2041.

41. Mazur G, Wróbel T, Butrym A, Kapelko-Słowik K, Poreba R, Kuliczkowski K. Increased
413 monocyte chemoattractant protein 1 (MCP-1/CCL-2) serum level in acute myeloid leukemia. *Neoplasma*.
414 2007;54(4):285-289.

415 42. Zhang L, Zhang M, Wang L, et al. Identification of CCL4 as an Immune-Related Prognostic
416 Biomarker Associated With Tumor Proliferation and the Tumor Microenvironment in Clear Cell Renal
417 Cell Carcinoma. *Front Oncol.* 2021;11:694664.

418 43. Hashwah H, Bertram K, Stirm K, et al. The IL-6 signaling complex is a critical driver, negative
419 prognostic factor, and therapeutic target in diffuse large B-cell lymphoma. *EMBO Molecular Medicine*.
420 2019;11(10):e10576.

421 44. Mozas P, Rivas-Delgado A, Rivero A, et al. High serum levels of IL-2R, IL-6, and TNF- $\alpha$  are 422 associated with higher tumor burden and poorer outcome of follicular lymphoma patients in the rituximab 423 era. *Leukemia Research*. 2020;94:106371.

- 424 45. Koukourakis MI, Kambouromiti G, Pitsiava D, Tsousou P, Tsiarkatsi M, Kartalis G. Serum C-
- 425 reactive Protein (CRP) Levels in Cancer Patients are Linked with Tumor Burden and are Reduced by
- 426 Anti-hypertensive Medication. *Inflammation*. 2009;32(3):169-175.
- 427 46. Choi S, You S, Kim D, et al. Transcription factor NFAT5 promotes macrophage survival in 428 rheumatoid arthritis. *J Clin Invest*. 2017;127(3):954-969.
- 429 47. Van Coillie E, Van Damme J, Opdenakker G. The MCP/eotaxin subfamily of CC chemokines.
  430 *Cytokine Growth Factor Rev.* 1999;10(1):61-86.
- 431 48. Yoshimura T. The chemokine MCP-1 (CCL2) in the host interaction with cancer: a foe or ally?
  432 *Cell Mol Immunol.* 2018;15(4):335-345.
- 433 49. Mittal P, Wang L, Akimova T, et al. The CCR2/MCP-1 Chemokine Pathway and Lung
  434 Adenocarcinoma. *Cancers (Basel)*. 2020;12(12):3723.
- 435 50. Wang R, Huang K. CCL11 increases the proportion of CD4+CD25+Foxp3+ Treg cells and the 436 production of IL $\Box$ 2 and TGF $\Box$  $\beta$  by CD4+ T cells via the STAT5 signaling pathway. *Mol Med Rep.* 437 2020;21(6):2522-2532.
- 438 51. Yang J, Hawkins OE, Barham W, et al. Myeloid IKKβ Promotes Antitumor Immunity by
  439 Modulating CCL11 and the Innate Immune Response. *Cancer Research*. 2014;74(24):7274-7284.
- 440 52. Conforti F, Pala L, Goldhirsch A. Different effectiveness of anticancer immunotherapy in men
  441 and women relies on sex-dimorphism of the immune system. *Oncotarget*. 2018;9(58):31167-31168.
- Kim SY, Lee S, Lee E, et al. Sex-biased differences in the correlation between epithelial-tomesenchymal transition-associated genes in cancer cell lines. *Oncol Lett.* 2019;18(6):6852-6868.
- 444 54. Zhu Y, Shao X, Wang X, Liu L, Liang H. Sex disparities in cancer. *Cancer Lett.* 2019;466:35-38.

445	55.	Pinheiro I, Dejager L, Libert C. X-chromosome-located microRNAs in immunity: might they
446	explain	male/female differences? The X chromosome-genomic context may affect X-located miRNAs
447	and dov	wnstream signaling, thereby contributing to the enhanced immune response of females. Bioessays.
448	2011;33	3(11):791-802.

Klein SL, Flanagan KL. Sex differences in immune responses. *Nature Reviews Immunology*.
2016;16(10):626-638.

451 57. Afsahi A, Burchett R, Baker CL, Moore AE, Bramson JL. Constitutive expression of interleukin-

452 27 diminishes proinflammatory cytokine production without impairing effector function of engineered T

453 cells. *Cytotherapy*. 2023;25(9):913-919.

454 58. Postal M, Vivaldo JF, Fernandez-Ruiz R, Paredes JL, Appenzeller S, Niewold TB. Type I 455 interferon in the pathogenesis of systemic lupus erythematosus. *Curr Opin Immunol*. 2020;67:87-94.

# 457 Table 1: Baseline and post-treatment clinical characteristics

Detion t aliminal above stavistics	Total	Male	Female
Patient clinical characteristics	N=67	N=46	N=21
Age-Median (range, years)	63 (25-77)	64.5 (25-77)	61 (30-74)
Males (%)	68.7	-	-
Number of prior therapies	3 (2-6)	3 (2-6)	3 (2-6)
(median, range)			
Prior autologous stem cell	40.3	37	47.6
transplantation (%)			
Disease Type			
Diffuse large B-cell lymphoma	46 (68.7)	35 (76)	11 (52.4)
(DLBCL), no. (%)			
Primary mediastinal B-cell	7 (10.4)	5 (11)	2 (9.5)
lymphoma, no. (%)			
Transformed follicular lymphoma	12 (17.9)	5 (11)	7 (33.3)
(TFL), no. (%)			
Unknown (%)	2 (3)	1 (2)	1 (4.8)
Type of Therapy			
Axicabtagene ciloleucel, no. (%)	45 (67.1)	29 (63)	16 (76.2)
Tisagenlecleucel, no. (%)	22 (32.8)	17 (37)	5 (23.8)
Treatments			
3-month response <sup>a</sup>	Total (N=65)	Total (N=45)	Total (N=20)
OR, no. (%)	33 (50.8)	23 (51.1)	10 (50)
CR, no. (%)	26 (40.0)	16 (35.6)	10 (50)
NR, no. (%)	32 (49.2)	22 (48.9)	10 (50)
LDH-Median (U/l)	254	253.5	276

458

<sup>459 &</sup>lt;sup>a</sup>CR: Complete response, PR: Partial response, OR: Overall response (CR+PR), NR: No response

<sup>460 (</sup>Progressive disease, Stable disease, Death); LDH: Lactate Dehydrogenase

Figure 1. Male patients with higher pre-treatment tumor burden show poorer survival after treated

1.

11

#### **Figure Legends** 462

463

464

465	with anti-CD19 CAR T-cells. Association of baseline LDH levels with overall survival (OS), and
466	progression-free survival (PFS) in both male and female (A), only male (B), or only female (C), LBCL
467	patients. P<0.05; Males, n=46; Females, n=21; Yes, n=45; Kym, n=22. LDH cut-off, 250 U/l
468	
469	Figure 2. Male patients with higher pre-treatment CRP abundance show poorer survival upon
470	treatment with anti-CD19 CAR T-cells. Association of baseline CRP with overall survival (OS), and
471	progression-free survival (PFS) in both male and female (A), or only male (B), or only female (C), LBCL
472	patients. P<0.05; Males, n=46; Females, n=21; Yes, n=45; Kym, n=22.
473	
474	Figure 3. Baseline cytokine and chemokine levels in male and female LBCL patients. Pre-treatment
475	relative abundance of cytokines and chemokines was compared in the serum of male and female LBCL
476	patients. P<0.05; Males, n=42; Females, n=20; Yes, n=42; Kym, n=20.

477

478 Figure 4. Male patients with elevated pre-treatment abundance of IL-8, Eotaxin-1 and MIP-1ß show poorer PFS upon treatment with anti-CD19 CAR T-cells. Association between relative 479 480 abundance of the indicated cytokines and PFS in both male and female, or only male or only female 481 LBCL patients. P<0.05; Males, n=42; Females, n=20; Yes, n=42; Kym, n=20.

- 483 Figure 5. Male patients with elevated pre-treatment abundance of IL-6, IL-8, IL-27, Eotaxin-1,
- 484 MCP-1 and TNF-α show poorer OS upon treatment with anti-CD19 CAR T-cells. Association
- 485 between relative abundance of the indicated cytokines and OS in both male and female, or only male or
- 486 only female LBCL patients. P<0.05; Males, n=42; Females, n=20; Yes, n=42; Kym, n=20.

# Figure 1



# Figure 2









# Figure 4



# Figure 5